|Table of Contents|

Luteolin inhibits invasion,migration,and epithelial-mesenchymal transition of glioblastoma through GSK-3β/β-catenin pathway

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 22
Page:
4115-4122
Research Field:
Publishing date:

Info

Title:
Luteolin inhibits invasion,migration,and epithelial-mesenchymal transition of glioblastoma through GSK-3β/β-catenin pathway
Author(s):
JIANG Hang1; YOU Qiuxiang1; CHEN Bo2; ZENG Xue1; WANG Long3; ZHANG Yundong1
1.Center of Neuropathies，the Third Affiliated Hospital of Chongqing Medical University，Chongqing 401120，China；2.College of Pharmacy,Chongqing Medical University，Chongqing 400016，China；3.Department of Neurosurgery，the First Affiliated Hospital，Army Medical University，Chongqing 400038，China.
Keywords:
glioblastoma; luteolin; invasion and migration; epithelial-mesenchymal transition; GSK-3β/β-catenin signaling pathway
PACS:
R739.4
DOI:
10.3969/j.issn.1672-4992.2023.22.004
Abstract:
Objective:To investigate the effect of luteolin on the invasion and metastasis ability of human glioma U87 and U251 cell lines and its mechanism.Method:Human glioma U87 and U251 cells were cultured in vitro and randomly divided into control group and luteolin group in the logarithmic growth phase.Cell viability,migration and invasiveness of glioma cells were detected by CCK-8 test,scratch test and Transwell test.Western blot test and immunofluorescence test were used to detect the effects of luteolin on epithelial-mesenchymal transition(EMT) related protein of glioblastoma and GSK-3β/β-catenin signaling pathway.The effects of luteolin on the expression of proteins,migration and invasiveness were validated by treating U87 and U251 cells with a GSK-3β/β-catenin signaling pathway inhibitor (G6983) or agonist (LiCl).The effects of luteolin on tumor weight and volume in vivo were observed by the tumorigenesis experiment in nude mice.Results:The results showed that luteolin inhibited the activity of glioma U87 and U251 cells in a concentration-dependent manner.The scratch test and Transwell test showed that the cell invasion and migration ability was reduced in the luteolin treatment group compared to the control group (P<0.05).Luteolin treatment made glioma cells change from mesenchymal morphology to epithelial morphology.Compared with the control group,the luteolin treatment could down-regulate the level of N-cadherin,Vimentin and β-catenin (cytoplasm,nucleus),p-GSK-3β (Ser9),while up-regulate the levels of E-cadherin protein (P<0.05).G6983 can enhance the effect of luteolin on EMT and GSK-3β/β-catenin signaling pathway.LiCl can reverse the influence of luteolin on EMT,GSK-3β/β-catenin signaling pathway,invasion and migration ability of glioma.In vivo experiments showed that compared with the control group,the luteolin treatment could reduce tumor volume and mass (P<0.05).Conclusion:Luteolin can inhibit the invasion and migration of glioma U87 and U251 cells.Its mechanism may be related to the regulation of GSK-3β/β-catenin signaling pathway and EMT process.

References:

［1］ SCHAFF LR,MELLINGHOFF IK.Glioblastoma and other primary brain malignancies in adults:A review［J］.JAMA,2023,329(7):574-587.
［2］ TANAKA S,LOUIS DN,CURRY WT,et al.Diagnostic and therapeutic avenues for glioblastoma:no longer a dead end［J］.Nat Rev Clin Oncol,2013,10(1):14-26.
［3］ PAWLOWSKI KD,DUFFY JT,BABAK MV,et al.Modeling glioblastoma complexity with organoids for personalized treatments［J］.Trends Mol Med,2023,29(4):282-296.
［4］ OSTROM QT,GITTLEMAN H,LIAO P,et al.CBTRUS statistical report:primary brain and central nervous system tumors diagnosed in the United States in 2007-2011［J］.Neuro Oncol,2014,16(Suppl 4):v1-v63.
［5］ ORAIOPOULOU ME,TZAMALI E,PAPAMATHEAKIS J,et al.Phenocopying glioblastoma:A review［J］.IEEE Rev Biomed Eng,2023,16:456-471.
［6］ MAY AM,BATOON L,MCCAULEY LK,et al.The role of tumor epithelial-mesenchymal transition and macrophage crosstalk in cancer progression［J］.Curr Osteoporos Rep，2023,21(2):117-127.
［7］ HUANG Y,HONG W,WEI X.The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis［J］.J Hematol Oncol,2022,15(1):129-156.
［8］ BRABLETZ T,KALLURI R,NIETO MA,et al.EMT in cancer［J］.Nat Rev Cancer,2018,18(2):128-134.
［9］ LIN D,KUANG G,WAN J,et al.Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression［J］.Oncol Rep,2017,37(2):895-902.
［10］ PANDURANGAN AK,DHARMALINGAM P,SADAGOPAN SK,et al.Luteolin induces growth arrest in colon cancer cells through involvement of Wnt/β-catenin/GSK-3β signaling［J］.J Environ Pathol Toxicol Oncol,2013,32(2):131-139.
［11］ CETINKAYA M,BARAN Y.Therapeutic potential of luteolin on cancer［J］.Vaccines (Basel)，2023,11(3):554-584.
［12］ CAO D,ZHU GY,LU Y,et al.Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity［J］.Biomed Pharmacother,2020,129:110462.
［13］ ZANG MD,HU L,FAN ZY,et al.Luteolin suppresses gastric cancer progression by reversing epithelial-mesenchymal transition via suppression of the Notch signaling pathway［J］.J Transl Med,2017,15(1):52.
［14］ NIETO MA,HUANG RY,JACKSON RA,et al.EMT:2016［J］.Cell,2016,166(1):21-45.
［15］ SNCHEZ-TILL E,DE BARRIOS O,SILES L,et al.β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness［J］.Proc Natl Acad Sci USA,2011,108(48):19204-19209.
［16］ NABAVI SF,BRAIDY N,GORTZI O,et al.Luteolin as an anti-inflammatory and neuroprotective agent:A brief review［J］.Brain Res Bull,2015,119(Pt A):1-11.
［17］ IMRAN M,RAUF A,ABU-IZNEID T,et al.Luteolin,a flavonoid,as an anticancer agent:A review［J］.Biomed Pharmacother,2019,112:108612.
［18］ PRASHER P,SHARMA M,SINGH SK,et al.Luteolin:a flavonoid with a multifaceted anticancer potential［J］.Cancer Cell Int,2022,22(1):386.
［19］ ZANG M,HU L,ZHANG B,et al.Luteolin suppresses angiogenesis and vasculogenic mimicry formation through inhibiting Notch1-VEGF signaling in gastric cancer［J］.Biochem Biophys Res Commun,2017,490(3):913-919.
［20］ HSEU YC,LIN YC,RAJENDRAN P,et al.Antrodia salmonea suppresses invasion and metastasis in triple-negative breast cancer cells by reversing EMT through the NF-κB and Wnt/β-catenin signaling pathway［J］.Food Chem Toxicol,2019,124:219-230.
［21］ AGRAVAL H,YADAV U.MMP-2 and MMP-9 mediate cigarette smoke extract-induced epithelial-mesenchymal transition in airway epithelial cells via EGFR/Akt/GSK3β/β-catenin pathway:Amelioration by fisetin［J］.Chem Biol Interact,2019,314:108846.
［22］ ZHANG M,DU H,WANG L,et al.Thymoquinone suppresses invasion and metastasis in bladder cancer cells by reversing EMT through the Wnt/β-catenin signaling pathway［J］.Chem Biol Interact,2020,320:109022.
［23］ LIU J,XIAO Q,XIAO J,et al.Wnt/β-catenin signalling:function,biological mechanisms,and therapeutic opportunities［J］.Signal Transduct Target Ther,2022,7(1):3.
［24］ YU F,YU C,LI F,et al.Wnt/β-catenin signaling in cancers and targeted therapies［J］.Signal Transduct Target Ther,2021,6(1):307-331.
［25］ ZHANG Y,WANG X.Targeting the Wnt/β-catenin signaling pathway in cancer［J］.J Hematol Oncol,2020,13(1):165.
［26］ STAMBOLIC V,WOODGETT JR.Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation［J］.Biochem J,1994,303(Pt 3):701-704.
［27］ YANG W,WU PF,MA JX,et al.Sortilin promotes glioblastoma invasion and mesenchymal transition through GSK-3β/β-catenin/twist pathway［J］.Cell Death Dis,2019,10(3):208.
［28］ HAN M,WANG S,FRITAH S,et al.Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/β-catenin signalling［J］.Brain,2020,143(2):512-530.

Memo

Memo:
重庆医科大学附属第三医院科研孵化项目（编号：KY19026）
Last Update: 1900-01-01